Kyverna Therapeutics Inc

Business Description

Kyverna Therapeutics is a clinical-stage company based in Emeryville, California, that develops cell-based treatments for people living with autoimmune diseases. Its primary focus is a therapy called KYV-101, which is being tested across several serious conditions including stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis. The company has additional treatments in development and works with Intellia Therapeutics to advance a next-generation therapy that uses donor cells rather than a patient's own. Founded in 2018, Kyverna has built a pipeline aimed at addressing diseases where the immune system attacks the body's own tissues.